Alessandro Gronchi

Chair Sarcoma Service - Department of Surgery - National Cancer Institute - Milan - Italy.

[Annals of Surgical Oncology @AnnSurgOncol]

Featured: Well-Differentiated #Liposarcoma of the Psoas Muscle: A Distinct Anatomic Subset with Highly Favorable Outcomes @alegronchi

https://t.co/SgK9kZSMgJ

@ZaidAbdelsattar
@SyedAAhmad5
@SocSurgOnc

[Dario Callegaro @DCalleMD]

The #Sarculator app update is now live!
This comes together with our @TheLancetOncol paper introducing #BayeSarc, a Bayesian sequential learning approach to refine prognostication in extremity soft tissue #sarcoma.
Paper: https://t.co/gQuFERjCqu
App: https://t.co/4mLSfv7zE3

[Dario Callegaro @DCalleMD]

The challenge of #surgonc is not only technical. It is about generating #evidence, making difficult decisions, organizing care, and keeping #innovation aligned with #patient benefit. @alegronchi opening this conversation @IstTumori at ‘The challenge of surgical oncology’.

[Italian Sarcoma Group @ItaSarcomaGroup]

Proud to host the ISG–Patient Associations Meeting at #ISG2026.
From national networks to legislative progress, today’s program reflects our shared commitment to listen, collaborate, and act for people living with rare tumors.

Together, we move beyond paradigms. 💛

[Dario Callegaro @DCalleMD]

The XXIX Annual Meeting of the Italian Sarcoma Group kicks off in Palermo 🇮🇹

250 attendees gathered to share science, collaboration, and new ideas in #sarcoma care. Looking forward to inspiring discussions over the next days! @ItaSarcomaGroup @SilviaStacchia @annamariafrezza

[BJS Open @BjsOpen]

Diagnosis and treatment of primary soft tissue sarcomas: comprehensive review
➡️https://t.co/nkO4PMq0Su

This review outlines current diagnostic and treatment strategies for localized primary soft tissue sarcomas, with a separate focus on extremity/trunk and retroperitoneal disease. Key points include recent therapeutic advances, multidisciplinary management, and the centralization of care in high-volume centres to optimize outcomes.

👏👏👏Fahima Dossa , Eldad Elnekave , Aisha B Miah , Catherine Mitchell , Sarah Watson , @alegronchi , @FioreDoc
#SoMe4Surgery #MedTwitter #SurgEd #Surgery @BJSAcademy @BJSurgery

[Fahima Dossa, MD PhD @fdossa]

Building on terrific #SSO2026 and @TARPSWG meetings, check out our📄on current dx & tx strategies for soft tissue sarcoma @BjsOpen, including recent technical advances and multiD approaches

@ctosociety @SocSurgOnc @ESSOnews @_CSSO @FioreDoc @alegronchi

https://t.co/5NrjCuVDxI

[TARPSWG @TARPSWG]

Want to join us? Register for free membership at https://t.co/cBzTf7c5Vx
And save the date for next meeting in November 2026 in Seoul (in connection with @ctosociety meeting)

[TARPSWG @TARPSWG]

#Guidelines update for primary RPS planned for 2028
New #Guidelines specific for pelvic sarcoma underway
#ERAS projects to define official protocols for RPS

[TARPSWG @TARPSWG]

Much to come for #retroperitoneal #sarcoma: #STRASS3 for neoadjuvant tx in LPS will include ICI?
#RESAR registry now includes >3800 pts and new analyses are ongoing
#Delphi consensus to standardize terminology and approach to RPS expected in 2027

[TARPSWG @TARPSWG]

TARPSWG Meeting was successful once again this year! Thanks to #SSO2026 for hosting us in Phoenix 🌵🌵😀

[Marco Fiore, MD, FACS, FEBSh @FioreDoc]

Great to be in Phoenix for #SSO2026. Connecting with Sug Oncs worldwide amazing as always @alegronchi

[Alessandro Gronchi @alegronchi]

Thanks for coming over. It was great to spend some time together!

[Ashley Drohan @drohan_ashley]

Sarcoma family dinner 💛thank you @SilviaStacchia and @alegronchi for welcoming us into your home, workplace and international sarcoma family! @TARPSWG @ctosociety @UofTSurgOnc

[Alessandro Gronchi @alegronchi]

5/ If we want to improve outcomes, it’s time to change the paradigm.
#Sarcoma #RetroperitonealSarcoma #PrecisionOncology #AIinMedicine #CancerResearch, @ctosociety @ItaSarcomaGroup @eClinicalMed @ESSOnews @UofTSurgOnc @IstTumori @SocSurgOnc @TARPSWG

[Alessandro Gronchi @alegronchi]

1/ 🚨 When surgery is not enough: time to rethink patient selection in #retroperitoneal #sarcoma. Are we operating on tumor biology we don’t yet understand?
In primary RPS, ~20% of patients recur within 6 months after surgery — with survival comparable to unresected patients.

[Alessandro Gronchi @alegronchi]

4/ The future is not just better surgery — it’s better selection:
🔬 biomarkers
🧠 AI prediction
💊 smarter neoadjuvant strategies

[Italian Sarcoma Group @ItaSarcomaGroup]

Capire meglio i sarcomi, ascoltare esperti e testimonianze, scoprire il ruolo delle associazioni nella ricerca e nel supporto dei Pazienti: @ segui in streaming 👉 https://t.co/LGBkyI0r6F @FondFerrero @fumagallielena_ @alegronchi @SilviaStacchia @DAmbrosio_MD

[Dario Callegaro @DCalleMD]

When p > 0.05 is not the end of the conversation. Fantastic Grand Round by @fdossa on how statistical misunderstandings can shape (and misshape) treatment decisions. A must-hear for clinicians. #sarcoma #clinicaltrials #statistics #oncology #surgery